SEC-sourced researchBeta

CAI

Caris Life Sciences, Inc.

US markets

Data passport

CIK: 0002019410
Exchange: Nasdaq
Business activity: — · SIC 8071
Financial inputs: 6/6
Filing date: Sep 23, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 6:01 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

CAI · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	306,128,000.0000	Mar 3, 2026
December 2024	412,260,000.0000	Mar 3, 2026
December 2025	812,033,000.0000	Mar 3, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	812,033,000.0000	-68,088,000.0000	83,155,000.0000	1,125,663,000.0000	548,356,000.0000	Mar 3, 2026
December 2024	412,260,000.0000	-281,890,000.0000	-245,199,000.0000	343,734,000.0000	620,921,000.0000	Mar 3, 2026
December 2023	306,128,000.0000	-341,415,000.0000	-276,100,000.0000	—	—	Mar 3, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$812.03M	December 2025	Mar 3, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$412.26M	December 2024	Mar 3, 2026	10-K
Net incomeNetIncomeLoss	-$68.09M	December 2025	Mar 3, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$83.16M	December 2025	Mar 3, 2026	10-K
Total assetsAssets	$1.13B	December 2025	Mar 3, 2026	10-K
Total liabilitiesLiabilities	$548.36M	December 2025	Mar 3, 2026	10-K

New filings

Explore methodology ↗